| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 6th January 2021 | Jerome B Zeldis | 1,650 | Grant/award etc. | $0.00 | |
| 28th May 2020 | Jerome B Zeldis | 1,000 | Open or private purchase | $10.49 | $10,488.90 |
| 29th January 2020 | Jerome B Zeldis | 1,650 | Grant/award etc. | $0.00 | |
| 19th November 2019 | Christopher J Schaber | 10,770 | Open or private purchase | $0.93 | $10,016.10 |
| 19th November 2019 | Jerome B Zeldis | 2,000 | Open or private purchase | $0.93 | $1,850.00 |
| 23rd September 2019 | Diane L. Parks | 14,940 | Open or private purchase | $0.93 | $13,870.30 |
| 19th September 2019 | Jerome B Zeldis | 4,000 | Open or private purchase | $0.94 | $3,740.00 |
| 28th June 2019 | Mark E. Pearson | 78,338 | Grant/award etc. | $0.71 | $55,619.98 |
| 22nd May 2019 | Jerome B Zeldis | 1,097 | Exercise of derivative | $6.85 | $7,514.45 |
| 22nd May 2019 | Jerome B Zeldis | 20,000 | Exercise of derivative | $3.40 | $68,000.00 |
Soligenix
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. The company operates through the following segments: BioTherapeutics and Vaccines/BioDefense. It offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of T-cell lymphoma.
Ticker: SNGX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 812796
Employees: 16
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
